Type 1 Diabetes Clinical Trials in Indianapolis, Indiana

7 studies are recruiting for type 1 diabetes in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

   This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evalua…

   Stage

   Phase 1

   Ages

   12 to 35

   Site

   Riley Hospital for Children- Indiana University, Indianapolis, Indiana

   Locations

   45 in total

   Run by

   COUR Pharmaceutical Development Company, Inc.

   See if you can join NCT06783309 on ClinicalTrials.gov

2. A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

   This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with recent-onset stage 3 T1D.

   Stage

   Phase 1

   Ages

   9 to 20

   Site

   Indiana University, Indianapolis, Indiana

   Locations

   10 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07061574 on ClinicalTrials.gov

3. SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

   This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).

   Stage

   Phase 2

   Ages

   5 to 40

   Site

   IUH - Riley Hospital for Children - Riley Outpatient Center - Pediatric Diabetes & Endocrinology, Indianapolis, Indiana

   Locations

   70 in total

   Run by

   SAb Biotherapeutics, Inc.

   See if you can join NCT07187531 on ClinicalTrials.gov

4. The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

   Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweigh…

   Stage

   Phase 2

   Ages

   11 to 18

   Site

   Indiana University School of Medicine, Indianapolis, Indiana

   Run by

   Heba M. Ismail

   See if you can join NCT05414409 on ClinicalTrials.gov

5. Denosumab for Type 1 Diabetes

   Type 1 diabetes (T1D) arises from abnormal immune cell-mediated injury to beta cells that make insulin. The injured beta cells can then no longer make the needed amount of insulin to stay healthy. However, in the early stages of T1D, some beta cells are still alive and functioning. Treatment to pro…

   Stage

   Phase 1

   Ages

   18 to 50

   Site

   Indiana University, Indianapolis, Indiana

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06524960 on ClinicalTrials.gov

6. Registry for Stage 2 Type 1 Diabetes

   Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to del…

   Stage

   Not phased

   Ages

   Any age

   Site

   Indiana University Health Riley Hospital for Children- Site Number : 8400004, Indianapolis, Indiana

   Locations

   37 in total

   Run by

   Sanofi

   See if you can join NCT06481904 on ClinicalTrials.gov

7. To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

   The goal of this clinical trial is to evaluate the efficacy and safety of Medtronic 780G automated insulin delivery system in adult persons with type 1 diabetes and gastroparesis.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Indiana University Health, Univeristy hospital, Indianapolis, Indiana

   Run by

   Viral N. Shah

   See if you can join NCT07287943 on ClinicalTrials.gov